Identifying and Validating Causal Genetic Alterations in Human Breast Cancer by Ethier, Stephen P.
Breast Cancer Research and Treatment 78: 285–287, 2003.
© 2003 Kluwer Academic Publishers. Printed in the Netherlands.
Introduction
Identifying and validating causal genetic alterations
in human breast cancer
Stephen P. Ethier
Department of Radiation Oncology, Division of Radiation and Cancer Biology, The University of Michigan Health
System, and the University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
Key words: breast cancer oncogene, gene amplification
Summary
An important mechanism for the activation of proto-oncogenes in human breast and other cancers is gene am-
plification, which results in gene overexpression at both the message and the protein levels. Recent studies have
demonstrated that oncogenes rarely if ever become amplified in isolation, but rather are present on large amplicons
that contain multiple genes. More detailed analysis of these amplicons has revealed the presence of many candidate
breast cancer oncogenes. The broad goal of this issue of Breast Cancer Research and Treatment is to review the
current state of our understanding of the causal role of defined genetic alterations that occur in human breast
cancers, and to discuss the case for the mechanistic significance of several candidate oncogenes. As will be seen,
these studies have revealed a remarkable genetic complexity and heterogeneity in human breast cancer that must
be dissected in order to improve our mechanistic understanding of disease progression, and to develop effective
new drugs against relevant molecular targets.
Defining causal genetic alterations in human
breast cancer
This special edition of Breast Cancer Research and
Treatment is devoted to reviewing the state of our
understanding of the causal genetic alterations that
underlie the majority of human breast cancers. It is
important that the true genetic causes of human breast
cancer be defined in order to clearly understand the
mechanistic basis of breast cancer progression. In ad-
dition, it is now clear from the early clinical trials
of targeted therapeutics, that the products of genes
that are most directly linked to the expression of neo-
plastic phenotypes provide the best targets for new
drug development.
As often happens in science, advances in our
knowledge on the genetics of human breast cancer has
served to cloud, more than it has served to clarify,
our understanding of the genetic basis of breast can-
cer. This, in itself, serves as an important reminder
of just how little we understand about human breast
cancer genetics. For example, just a few years ago,
one could have generated a simple list of likely hu-
man breast cancer genes, which would have included
HER-2, C-MYC, FGFR1, and perhaps some of the int
genes, such as FGF-3 and FGF-4 [1]. Further study of
each of these genes and their respective genetic loci
have demonstrated that with the exception of HER-2,
the genes listed above may serve as little more than
genetic markers for other more mechanistically rele-
vant genes that are present in the same regions of the
genome. This topic will be discussed in great detail
throughout this volume.
It can be argued that the only known and validated
human breast cancer oncogene is HER-2. It is the only
gene that has been strongly associated with human
breast cancer progression in studies of clinical mate-
rial [2, 3] that has also been shown to be transforming
in human mammary epithelial cells in vitro [4, 5],
to cause mammary tumor development in transgenic
mice [6, 7], and for which a targeted therapeutic has
been developed that has efficacy in the clinic [8, 9].
Thus, the case for HER-2 as a human breast cancer
oncogene is strong and is based on both correlative
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and mechanistic data. However, even for HER-2, the
mechanism by which the gene becomes activated as
an oncogene in human breast and other cancers has
demonstrated that the picture is more complicated than
would appear based on the evidence described above.
Thus, HER-2, like other candidate oncogenes, be-
comes activated by a process of gene amplification,
which results in large increases in copy number of the
gene, and which is accompanied by large increases in
message and protein levels. However, HER-2 does not
undergo gene amplification in isolation. Rather, HER-
2 is part of a large amplicon centered around chro-
mosome 17q12 that contains many amplified genes
in addition to HER-2. And, as will be discussed in
detail in the chapter by Jarvinen, some of the genes
on the amplicon may have mechanistic significance
and act either in concert with, or in addition to, the
transforming effects of HER-2. In addition, the HER-
2 story has served to illustrate the important scientific
principle that correlation does not prove causation in
an area that has direct clinical relevance. Again, as de-
scribed in detail by Jarvinen, correlative clinical data
have suggested a link between HER-2 amplification
and response to adriamycin containing chemotherapy
regimens. Despite this correlation, mechanistic data
from the laboratory to support that finding have not
been found. More recently, however, it has become
clear that another gene that is sometimes present on the
HER-2 amplicon, namely Topoisomerase II, is associ-
ated with adriamycin responsiveness [10]. The mech-
anistic connection between TOPO II overexpression
and response to adriamycin has been demonstrated in
the laboratory. Thus, studies of the HER-2 gene, and
more importantly, the HER-2 amplicon, have served
to illuminate an important principle of human cancer
genetics; that focal areas of gene amplification mark
the presence of dominantly acting oncogenes, and that
multiple genes on an amplicon may have a role in
breast cancer progression.
The majority of chapters in this volume are dedi-
cated to reviewing the state of our knowledge re-
garding the most common amplicons in human breast
cancer, and what we currently understand about the
candidate oncogenes present at those loci. As with
the HER-2 locus on chromosome 17q12, the other
common amplicons contain several genes that could,
in certain contexts, act as breast cancer oncogenes.
Donna Albertson will discuss the current state-of-the-
art in defining regions of gene amplification in breast
cancers. As indicated above, Jarvinen and Liu will
discuss the HER-2 amplicon, and Sinclair et al. will
describe a second amplicon on chromosome 17q21,
which also contains several interesting breast cancer
oncogenes. The chapter by Hodgson et al. details
the amplicon on chromosome 20q12-q13 that contains
at least three genes for which there is mechanistic
evidence for a role in breast cancer progression. The
chapter by Ormandy et al. will outline a particu-
larly interesting amplicon in breast cancer that centers
around chromosome 11q13. This amplicon has seen
the emergence and disappearance of a number of can-
didate genes over the years. The current view is that at
least two genes on that amplicon, CCND1 and EMS1,
are likely to play mechanistic roles in human breast
cancer. The unifying theme for all of these chapters is
that, without exception, each amplicon that has been
identified in human breast cancer contains more than
one candidate oncogene for which there is evidence
for a causal role in breast cancer development.
In the final chapter, Peter O’Connell will sum-
marize the state of our knowledge of an even more
complicated area of breast cancer genetics: the role of
loss of genetic material at specific loci as indicators of
putative tumor suppressor genes. This is an even more
difficult area of work because, unlike amplicons where
the search for oncogenes can be narrowed by focusing
on the subset of genes that are overexpressed, any and
all genes on chromosomal regions commonly lost in
breast cancer are potential candidate tumor suppressor
genes.
Mechanistic implications of focal areas
of gene amplification
Given our current understanding of the candidate
breast cancer genes present on focal amplicons, how
do we interpret the fact of their existence in breast
and other human cancers? The prevailing view just
a few years ago was that each amplicon harbored a
single oncogene. However, based on our current un-
derstanding of the plethora of candidate genes that
have been identified in a small number of amplicons,
we must now begin to consider an alternate view.
Thus, it may be that focal areas of gene amplifica-
tion emerge in human cancers non-randomly because
certain areas of the genome harbor multiple proto-
oncogenes in relatively close proximity. Furthermore,
it may be possible that multiple proto-oncogenes on a
single amplicon may interact mechanistically to drive
tumor progression. Indeed, it is not difficult to hypoth-
esize that the simultaneous overexpression of HER-2
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and Grb-7, which are commonly co-overexpressed
from the same amplicon, cooperate in the expression
of transformed phenotypes. Grb7 has been recently
linked to signaling via focal adhesion kinase (FAK),
which plays an important role in motility and inva-
sion [11–13]. We demonstrated that when HER-2 is
overexpressed, it interacts directly with FAK, and that
HER-2 overexpression yields a motile and invasive
phenotype [5, 14]. Thus, co-overexpression of HER-2
and Grb7 may be mechanistically relevant and may be
illustrative of the importance of amplicons containing
multiple genes that act together in cancer progression.
Focal areas of gene amplification may, therefore, be
an efficient mechanism for cells to activate multiple
oncogenes that cooperate to transform cells.
Breast cancer genes in tumors without focal
areas of gene amplification
Clearly, focal areas of gene amplification provide im-
portant areas of the genome in which to search for
breast cancer genes. However, it is important to keep
in mind that not all breast cancers exhibit defined
amplicons. Indeed, Albertson and colleagues have
recently estimated that only a fraction of all breast
cancers have these kinds of genetic alterations. The
remaining breast cancers either have low level chro-
mosomal changes in the majority of chromosomes, or
have structurally normal chromosomes, even though
they may be aneuploid. Thus, even after we have iden-
tified all of the causally relevant oncogenes present on
focal amplicons, there will still be an enormous chal-
lenge to understand the genetic basis of breast cancer
progression in the large fraction of tumors that remain.
As alluded to above, these studies are critically impor-
tant to the development of novel targeted therapeutic
agents. While correlative studies of genes and clinical
outcome may be sufficient for studies of prognosis and
for the identification of biomarkers, the development
of new therapies for breast cancer patients absolutely
depends on a mechanistic understanding of the genetic
basis of human breast cancer progression. The prin-
ciple that effective drugs against good targets yields
great clinical benefit has been proven with drugs such
as tamoxifen, herceptin (Trastuzumab) and Gleevec.
However, the clinical lessons learned so far with these
agents is that, despite their target specificity and ef-
fectiveness, more such agents directed against other
mechanistic targets must be developed so that remis-
sions can be converted into cures for patients with
breast and other cancers.
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